EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Personalized Treatment of Multiple Myeloma in Frail Patients

Jodi J Lipof, Nadine Abdallah, Brea Lipe

Current Oncology Reports · 2024-07 · 26 (7) · 744-753

DOI: 10.1007/s11912-024-01545-2 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Oncology Reports, online erschienen am 18.05.2024. Verfasst von Jodi J Lipof und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Precision Medicine, Frail Elderly. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE OF REVIEW: As the treatment landscape for multiple myeloma (MM) continues to expand at a rapid pace, management of older adults and frail patients becomes increasingly challenging. As these patients have traditionally been underrepresented on clinical trials, there is limited guidance on the optimal approach to frail patients with newly diagnosed multiple myeloma (NDMM) or relapsed and refractory multiple myeloma (RRMM). RECENT FINDINGS: Frailty is an independent predictor of tolerability and response to antineoplastic treatment. Stringent eligibility criteria have often excluded these patients, but recently some large trials have included frailty sub-analyses to help guide management. In general, triplet regimens are preferred to doublet regimens in this population and enrollment on a clinical trial should be prioritized when possible. In this review, we summarize the MM frailty scoring tools that have been developed to identify and assess this vulnerable population. We present the clinical trials over the past decade that have enrolled frail patients and/or have included subgroup analyses to help elucidate the response and tolerability of different regimens in this underrepresented group. We provide practical advice regarding assessment and management of frail patients NDMM and RRMM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaPrecision MedicineFrail ElderlyHumansAntineoplastic Combined Chemotherapy ProtocolsFrailtyAged

Stichwörter der Autor:innen

Frail patientsMultiple myelomaOlder adults with myelomaTransplant ineligible

Autor:innen und Institutionen

  • Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, USA.
  • Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN, USA.
  • Division of Hematology/Oncology, Department of Medicine, University of Rochester Medical Center, Wilmot Cancer Institute, Rochester, NY, USA. Brea_Lipe@URMC.Rochester.edu.

Zitieren

APA

Lipof, J. J., Abdallah, N., & Lipe, B. (2024). Personalized Treatment of Multiple Myeloma in Frail Patients. Current Oncology Reports, 26(7), 744-753. https://doi.org/10.1007/s11912-024-01545-2

Vancouver

Lipof JJ, Abdallah N, Lipe B. Personalized Treatment of Multiple Myeloma in Frail Patients. Current Oncology Reports. 2024;26(7):744-753. doi:10.1007/s11912-024-01545-2

BibTeX
@article{Lipof2024,
  author = {Lipof, Jodi J and Abdallah, Nadine and Lipe, Brea},
  title = {Personalized Treatment of Multiple Myeloma in Frail Patients},
  journal = {Current Oncology Reports},
  year = {2024},
  volume = {26},
  number = {7},
  pages = {744--753},
  doi = {10.1007/s11912-024-01545-2}
}
Kostenlos starten →